

## CURRICULUM VITAE

### **Markus G. Manz, M.D.**



#### **Position and Work Address**

- Professor/Ordinarius of Hematology University of Zürich (UZH)
- Director Department of Hematology and Oncology USZ
- Director Hematology USZ
- Director a.i. Oncology USZ
- Chairman Leukemia-, Lymphoma-, Myeloma-Center USZ
- Steering Committee Cancer Network Zurich UZH

Rämistrasse 100  
CH-8091 Zürich  
Switzerland

Ph: + 41 44 255 38 99  
Fax: + 41 44 255 45 60  
e-mail: [markus.manz@usz.ch](mailto:markus.manz@usz.ch)  
[www.haematologie-onkologie.usz.ch](http://www.haematologie-onkologie.usz.ch)

#### **Education**

1989 – 1995 University of Tuebingen Medical School, Germany

#### **Clinical Training**

1995-1999 Resident Physician, Department of Medicine,  
& Department of Hematology/Oncology/Immunology University of  
Tuebingen Medical School, Germany

2004-2006 Clinical Fellow, Department of Hematology/Oncology/Immunology  
University of Tuebingen Medical School, Germany

#### **Licensure and Board Qualification**

2006 Internal Medicine, Germany/European Union  
2007 Hematology and Oncology, Germany/European Union  
2009 Internal Medicine license recognition Switzerland (FMH)  
2009 Hematology license recognition Switzerland (FMH)

**Research Training**

- 1992-1996 Thesis (Dissertation):  
 “Tumornecrosis factor  $\beta$  Gen-Polymorphisms in myasthenia gravis“  
 Department for Hematology/Transplantation Immunology  
 University of Tuebingen Medical School, Germany
- 1999-2002 Postdoctoral Research Fellow  
 Department of Pathology and Developmental Biology  
 Stanford University Medical School, USA
- 02/2007 Habilitation (Venia Legendi in Internal Medicine)  
 University of Tuebingen Medical School, Germany

**Academic and Hospital Appointments**

- 2002-2004 Research Group Leader  
 Institute for Research in Biomedicine (IRB)  
 Bellinzona, Switzerland
- 04/2004-09/2006 Associate research group leader  
 Institute for Research in Biomedicine (IRB)  
 Bellinzona, Switzerland
- 3-9/2006 Physician, Department of Hematology/Oncology/Immunology University  
 of Tuebingen Medical School, Germany  
 Chairman: Prof. Dr. Lothar Kanz
- 08/2006 Elected “primo loco” as Director (W3) of the “Department of Cellular  
 Therapeutics and Research” at the Essen University Medical School,  
 Germany (refused 10/2006)
- 10/2006-08/2009 Research Group Leader  
 Institute for Research in Biomedicine (IRB)  
 Bellinzona, Switzerland
- 11/2006-08/2009 Attending Department of Hematology,  
 Oncology Institute of Southern Switzerland, Bellinzona  
 Chairman: Prof. Dr. Franco Cavalli
- 02/2007-08/2009 Privatdozent/PD  
 Medical Faculty, Eberhard-Karls-University Tuebingen, Germany
- 07/2008-08/2009 Vice-Director IRB, Bellinzona, Switzerland
- 09/2009-12/2011 Associate research group leader IRB, Bellinzona, Switzerland
- 09/2009-ongoing Professor/Ordinarius of Hematology at the Medical Faculty and Director  
 Hematology at the University and University Hospital of Zürich,  
 Switzerland
- 11/2010-ongoing Professor with “Promotionsrecht” at the Mathematical and Natural  
 Sciences Faculty at the University of Zürich
- 01/2012-05/2017 Chairman Steering Committee Cancer Network Zürich (UZH/ETHZ)
- 06-2017-ongoing Steering Committee Cancer Network Zürich (UZH/ETHZ)
- 08/2013-ongoing Lead Clinical Research Priority Program UZH (“Human Hemato-Lymph.  
 Diseases”)
- 01/2014-ongoing Director Leukemia-, Lymphoma-, Myeloma-Center USZ
- 02/2014-ongoing Cancer Biology PhD Program Steering Committee Member  
 (Life Sciences UZH/ETHZ)
- 2016-ongoing Secretary Swiss Society of Hematology
- 07/2016-ongoing Director Department of Hematology and Oncology USZ
- 01/2017-ongoing Director a.i. Oncology USZ

**Honors and Awards**

- 1999 Postdoctoral Research Fellowship, Deutsche Krebshilfe (<https://www.krebshilfe.de/>)
- 2002 Swissbridge Award (<http://www.swissbridge.ch>)
- 2004 Artur-Pappenheim-Award, German Society of Hematology and Oncology (DGHO;  
<https://www.dgho.de>)
- 2008 San Salvatore Foundation Award (<http://www.fondazioneansalvatore.ch/>)
- 2010 Ellermann Award Hematology 2009, Swiss Society of Hematology (SGH;  
<http://www.sgh-ssh.ch/>)
- 2016 Otto Naegeli Award (<http://www.otto-naegeli-preis.ch/>)
- 2017 Cloëtta Award (<http://www.cloetta-foundation.ch/de/cloetta-preis/>)

**Professional Organizations and Societies**

Swiss Society of Hematology (SGH, Secretary 2016-ongoing), Swiss Medical Association (FMH), Swiss Society for Allergology and Immunology (SSAI), German Society of Hematology and Oncology (DGHO), German Society of Internal Medicine (DGIM), European Society of Hematology (EHA, Sci Committee 2010-2013), European School of Hematology (Scientific Committee 2013-2015), American Society of Hematology (ASH), International Society of Experimental Hematology (ISEH), Henry Kunkel Society (HKS), Swiss Society of the Friends of the Weizmann Institute of Science (Board member), Charles Rodolphe Brupbacher Foundation (Sci Board), Swiss Stem Cell Network (SSCN), Cancer Network Zürich (CNZ, Chairman 2012-ongoing)

**Scientific Board Member**

Swiss Stem Cell Network (SSCN, 2013-ongoing)  
Charles Rodolphe Brupbacher Foundation (2011-ongoing)  
Justus Müller Stiftung (2015-ongoing)  
Swiss Soc. Friends of the Weizmann Institute of Science (2011-ongoing)  
International Society of Experimental Hematology (ISEH, 2015-ongoing)  
American Society of Hematology (ASH, 2015-ongoing)  
Swiss Society of Hematology (SGH, 2016 – ongoing)

**Editorial Board Member**

Blood Editorial Board (2013-2017)  
Blood Advances Associate Editor (2016-ongoing)

**Ad hoc Editorial Referee**

Blood, Cell Stem Cell, European Journal of Immunology, Hematologica-The Hematology Journal, Immunity, Nature, Nature Immunology, Nature Medicine, Nature Biotechnology, PLoS Biology, Proceedings of the National Academy of Sciences, The Journal of Experimental Medicine, The Journal of Immunology

**Ad hoc Industrial Consulting**

Amgen, Bristol-Myers Squibb, Celgene, Janssen Pharmaceutica, Novartis, Roche, Sanofi-Aventis, Teva Pharma

**Grant Review**

Swiss Cancer League, Swiss National Science Foundation (SNF), Swissbridge, Bill and Melinda Gates Foundation, Deutsche Forschungsgemeinschaft (DFG), Else Kröner-Fresenius Stiftung, Novo-Nordisk Foundation, Deutsche Krebshilfe

07.08.2017



M. Manz